Brazikumab is a human IgG2 monoclonal antibody targeting IL-23 that selectively binds to the p19 subunit of IL-23 and has a KD value of 0.138 nM against human IL-23 for Crohns disease (CD).
Purity:
>95.0%
CAS Number:
[1610353-18-8]
Target:
IL Receptor/Related
* VAT and and shipping costs not included. Errors and price changes excepted